IBBQInvesco Nasdaq Biotechnology ETF

Grow my money5y track recordRanked #1,020 of 2,960 in this goal

Seeks to track the investment results of the Nasdaq Biotechnology Index.

By Invesco · Launched 2021

Annual Cost

0.19%

#957 of 5,562 · low cost

Fund Size

$67M

#3,295 of 5,562 · mid-size

Return (1Y)Goal

+44.6%

Track Record

5 years

#2,392 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$14,439+44.4%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

Nasdaq Biotechnology Index

What it actually holds

By weight

Concentration

Top 10 holdings = 61.2% of fundconcentrated

Invesco Private Prime Fund

13.9%

Amgen Inc.

7.7%

Gilead Sciences, Inc.

7.1%

Vertex Pharmaceuticals Inc.

7.1%

Regeneron Pharmaceuticals, Inc.

6.2%

Invesco Private Government Fund

5.5%

Alnylam Pharmaceuticals, Inc.

4.5%

AstraZeneca PLC

3.7%

Insmed Inc.

3.4%

argenx SE

2.2%

Asset allocation

Stocks

100.0%

Cash

0.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

20.0%Moderate

Year-on-year price swings

Max drawdown

-37.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.55Decent risk-adjusted returns

Sortino (3Y)

0.78Moderate downside risk

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to track the investment results of the Nasdaq Biotechnology Index.
Strategy: Invests at least 90% of total assets in securities of the Nasdaq Biotechnology Index. The Index is a modified market-capitalization weighted index measuring performance of companies in the biotechnology and pharmaceuticals subsectors. It includes large-, mid-, and small-cap companies, weighted by market capitalization. The Fund employs full replication methodology, investing in all securities of the Index in proportion to their weightings.
Inception date: June 11, 2021
Fund family: Invesco